VEGF-mediated tumour angiogenesis: a new target for cancer therapy.
about
Effect of hypoxia on the expression of αB-crystallin in head and neck squamous cell carcinomaFacilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents.Solution structure of the major G-quadruplex formed in the human VEGF promoter in K+: insights into loop interactions of the parallel G-quadruplexesArginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis.In vitro footprinting of promoter regions within supercoiled plasmid DNA.The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents.Vascular endothelial growth factor and its receptors in multiple myeloma.Evidence of the formation of G-quadruplex structures in the promoter region of the human vascular endothelial growth factor geneαB-crystallin stimulates VEGF secretion and tumor cell migration and correlates with enhanced distant metastasis in head and neck squamous cell carcinomaCalpains as potential anti-cancer targetsPredicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels.Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric studyAntiangiogenic gene therapy.Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinomaAn antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cellsToward a new generation of vaccines: the anti-cytokine therapeutic vaccines.Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomasHuman telomere, oncogenic promoter and 5'-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics.In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model.Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis.Overview of formation of G-quadruplex structures.The pivotal role of VEGF in adipose-derived-stem-cell-mediated regeneration.A truncated plasminogen activator inhibitor-1 protein blocks the availability of heparin-binding vascular endothelial growth factor A isoforms.LncRNA as a Therapeutic Target for Angiogenesis.Expression of the vascular endothelial growth factor gene is inhibited by p73.Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent.The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients.TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression.A putative G-quadruplex structure in the proximal promoter of vegfr-2 has implications for drug design to inhibit tumor angiogenesis.Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging.Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levelsLong Non-Coding RNA Regulates Angiogenesis in Hindlimb Ischemia
P2860
Q21261248-3824DBC9-02CC-4209-9088-C92BC7743220Q24816211-A5B5078D-25E3-4305-A60F-966972506B3FQ27679870-021A26B3-84DC-4127-8AE4-AF468E17B3C7Q30864689-FCCB0854-F14F-420B-96AD-C963D155E1FBQ33594169-0084A3CC-6D9B-48A4-8B08-0ACC46C10668Q34011118-0F4DE18A-8FAD-4498-8791-BE8A1DA5E1F4Q34265556-08A7CD5F-187C-4AAF-9B5B-C73231A340E7Q34609291-7ADAA7F9-055B-47E3-A5B8-D0521193D556Q34626414-4A460709-BBA3-4F4F-805C-E593924FA694Q34793288-A9BD2C94-78D0-46C1-8463-053A03729031Q35210404-DE4836C2-2157-4139-9759-C8E37C2DCB35Q35765199-A40B80D1-58F5-47B4-8BD2-AA740CA14EB6Q36069788-EB36DA7D-AB48-4645-A630-F8EB89576962Q36397210-C95D7C76-843A-4E91-9ADB-F9F5CF67CB84Q36477682-CA927A11-B3C9-48BD-B294-341350F537CDQ36536313-B678A91B-C680-42D6-9DEB-34BC355225AAQ36617389-11FEE909-B958-4236-A9A4-CBFA318EA218Q36959489-00C3D31C-2781-453D-8692-0E4AD03F235AQ37165842-18121184-2744-459C-B4C0-DBEBF4D0A9E7Q37631817-ADB979FF-4E07-4773-9F34-2802B7F6A505Q37702161-0D72ABC9-2A39-401C-BF1C-227823339523Q37791174-C68E1D4C-A282-4291-B7A2-3F107109DD9BQ38361908-7B24448E-3E1A-4A8A-B909-68342ADA3271Q39009966-FF914BF0-42AA-44D0-B6E7-314156E604E8Q40865261-CAA4CEEC-3E92-460B-B7F8-52125269449FQ41011329-7921309E-F9AD-4BE2-856E-4C5D4CC69407Q42080528-C22B4647-F4B8-47B1-A2EE-B7A793BE3030Q43567478-6D2A2B60-7AD1-4BF0-9CB5-6AA93BE34515Q43968903-EBCF9178-D7ED-4981-8C2C-F8E0060199A4Q52582201-1E3F034D-0D4A-48A4-8644-5D8316A706C7Q55475521-A20CA38D-102B-4F88-85A9-86B138FE6AF0Q56765323-041CE770-B0A5-4BAF-87FD-DBC95E45658FQ57855535-3E15FBB0-CAFF-4F25-9C88-9A67A1298A4F
P2860
VEGF-mediated tumour angiogenesis: a new target for cancer therapy.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
VEGF-mediated tumour angiogenesis: a new target for cancer therapy.
@en
type
label
VEGF-mediated tumour angiogenesis: a new target for cancer therapy.
@en
prefLabel
VEGF-mediated tumour angiogenesis: a new target for cancer therapy.
@en
P1476
VEGF-mediated tumour angiogenesis: a new target for cancer therapy.
@en
P2093
Martiny-Baron G
P304
P356
10.1016/0958-1669(95)80111-1
P577
1995-12-01T00:00:00Z